[Perspectives on postgenome medicine: Gene therapy for AIDS].
Following the introduction of HAART(highly active anti-retroviral therapy) marked decreases in AIDS-related morbidity and mortality have been observed. Despite of the clinical success, recent work suggests that there are persistent viral replication in whom plasma HIV-RNA is consistently below detectable level. Furthermore, some experts even suggest that it will be difficult for many of the patients to continue the HAART because of the long-term side effects and drug resistance. Recent studies that supported the correlation of HIV-specific CD4-T cell(helper) response with the control of viral replication in vivo have promoted the development gene-based immunotherapy. However, further elucidation of viral pathogenesis in the patient under HAART will be required to develop the immunotherapeutic interventions.
Matsushita
S
S
Division of Clinical Retrovirology and Infectious Diseases, Center for AIDS Research, Kumamoto University.
Koito
A
A
D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000628:therapy* / Q000821:virology; D000818:Animals; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D004352:Drug Resistance, Microbial; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D019713:Receptors, CCR5 / Q000235:genetics; D014779:Virus Replication
D019713:Receptors, CCR5